Literature DB >> 12467964

Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies.

Hirokazu Kanegane1, Keiko Nomura, Toshio Miyawaki, Giovanna Tosato.   

Abstract

Most primary Epstein-Barr virus (EBV) infections are clinically inapparent, but occasionally EBV infection can cause acute infectious mononucleosis. EBV has been linked to a variety of hematologic and non-hematologic malignancies. Chronic active EBV (CAEBV) infection designates a recently identified EBV-associated syndrome characterized by a variety of serious hematological disorders, including malignant lymphoma. EBV was found to infect circulating T- and/or NK-cells in patients with CAEBV infection. These EBV-infected T- and/or NK-cells express EBNA-1, LMP-1, and LMP-2A, a type II form of EBV latency, which is also observed in nasopharyngeal carcinoma (NPC), Hodgkin's disease (HD), and peripheral T-cell lymphoma. CAEBV infections may thus represent a subset of EBV-associated T- and/or NK-cell lymphoproliferative disorders.

Entities:  

Mesh:

Year:  2002        PMID: 12467964     DOI: 10.1016/s1040-8428(02)00115-4

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  14 in total

1.  Epstein Barr-virus (EBV) associated T-cell clonopathy mimicking lymphomatous meningitis.

Authors:  D M Hermann; J Fehr; C L Bassetti
Journal:  J Neurol       Date:  2005-03-14       Impact factor: 4.849

Review 2.  Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies.

Authors:  Xueyi Zheng; Yuhua Huang; Kai Li; Rongzhen Luo; Muyan Cai; Jingping Yun
Journal:  Viruses       Date:  2022-05-10       Impact factor: 5.818

3.  BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma.

Authors:  Nenad Sejic; Lindsay C George; Rosemary J Tierney; Catherine Chang; Olga Kondrashova; Ruth N MacKinnon; Ping Lan; Andrew I Bell; Guillaume Lessene; Heather M Long; Andreas Strasser; Claire Shannon-Lowe; Gemma L Kelly
Journal:  Blood Adv       Date:  2020-10-13

4.  Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.

Authors:  Jiang Li; Qiu-yan Chen; Haoyuan Mo; Yi-lan Zhang; Zhou-feng Huang; Yi-xin Zeng
Journal:  Int J Biol Sci       Date:  2011-05-18       Impact factor: 6.580

5.  Cancer mortality in a Chinese population surrounding a multi-metal sulphide mine in Guangdong province: an ecologic study.

Authors:  Mao Wang; Hong Song; Wei-Qing Chen; Ciyong Lu; Qianshen Hu; Zefang Ren; Yan Yang; Yanjun Xu; Aiming Zhong; Wenhua Ling
Journal:  BMC Public Health       Date:  2011-05-16       Impact factor: 3.295

6.  Mycosis fungoides: is it a Borrelia burgdorferi-associated disease?

Authors:  S Miertusova Tothova; S Bonin; G Trevisan; G Stanta
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

Review 7.  Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target.

Authors:  Eric Tse; Yok-Lam Kwong
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

8.  Severe chronic active EBV infection in an adult patient: case report.

Authors:  Sang-Yoon Ha; Chul-Won Chung; Young H Ko
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

9.  Epstein-Barr-Virus-Positive B-Cell Lymphoma of Recipient Origin Despite of the Elimination of Clonally EBV-Infected T Cells by Allogeneic Stem Cell Transplantation in a Patient with Chronic Active EBV Infection.

Authors:  Masayuki Nagasawa
Journal:  Case Rep Transplant       Date:  2012-06-13

10.  Role of natural killer cells in innate protection against lethal ebola virus infection.

Authors:  Kelly L Warfield; Jeremy G Perkins; Dana L Swenson; Emily M Deal; Catharine M Bosio; M Javad Aman; Wayne M Yokoyama; Howard A Young; Sina Bavari
Journal:  J Exp Med       Date:  2004-07-12       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.